Faculty Profiles - TOYOOKA Shinichi

MISC - TOYOOKA Shinichi

Division display 541 - 560 of about 703 ／ All the affair displays >>

Does the Ex-Vivo Lung Evaluation System Affect Post-Transplant Graft Function in Swine Donation after Cardiac Death (DCD) Lung Transplantation?

S. Otani, T. Oto, K. Miyoshi, S. Yamamoto, T. Kakishita, M. Okazaki, O. Yoshida, N. Waki, S. Hori, S. Sugimoto, J. Soh, M. Yamane, S. Toyooka, Y. Sano, S. Miyoshi

JOURNAL OF HEART AND LUNG TRANSPLANTATION 29 ( 2 ) S164 - S164 2010.2

【Pancoast型肺癌の手術】選択術式肺尖部胸壁浸潤肺癌に対する手術

豊岡伸一, 宗淳一, 杉本龍士郎, 山根正修, 大藤剛宏, 吉増達也, 岡村吉隆, 佐野由文, 伊達洋至, 三好新一郎

胸部外科 63 ( 1 ) 57 - 64 2010.1

Language：Japanese Publisher：(株)南江堂

肺尖部胸壁浸潤肺癌の手術例13例を対象に、治療成績や手術アプローチを検討した。術前治療は12例に行われ、放射線単独療法3例、放射線化学療法9例であった。手術アプローチは、後方アプローチ4例、Masaokaらにより報告された前方アプローチもしくはその変法7例、Grunenwaldらにより報告された前方と後方アプローチの併用1例、前方と後正中アプローチの併用1例であった。その他、視野を確保するために2例で鎖骨を鎖骨頭から2/3切除し、4例で鎖骨を切断または胸鎖関節から外した。合併症としては、呼吸不全1例、術前には認めなかった反回神経麻痺1例、乳び胸1例、心房細動2例を認めたが、治療関連死亡はなかった。術後病理診断で、摘出標本中に腫瘍細胞の残存を認めなかったのは7例であった。全13例の3年生存率は61.0%、5年生存率は25.5%であり、術後放射線化学療法を施行した9例では3年生存率70.0%、5年生存率46.7%であった。

researchmap

Molecular Biology of Lung Cancer

Toyooka Shinichi, Mitsudomi Tetsuya, Soh Junichi, Yamamoto Hiromasa, Miyoshi Shinichiro

Haigan 50 ( 4 ) 329 - 341 2010

Language：Japanese Publisher：The Japan Lung Cancer Society

Recent advances in biotechnology have made it possible to explore the molecular pathogenesis of human lung cancer. Since the 1980s, various alterations, including mutations in the P53 and KRAS genes, allelic alterations like loss of heterozygosity, and DNA methylation of tumor-related genes have been extensively studied. In 2004, epidermal growth factor receptor (EGFR) gene mutation was discovered in non-small cell lung cancer (NSCLC) as an alteration that causes oncogene addiction. EGFR mutation is also significantly associated with sensitivity to EGFR-tyrosine kinase inhibitors (TKI), which has encouraged intensive studies not only on the EGFR gene but also on the EGFR family and its downstream genes. Furthermore, EML4-ALK fusion genes have been found in NSCLC, and as in EGFR-TKIs, an ALK inhibitor shows a drastic response in NSCLC with the EML4-ALK fusion gene. These discoveries demonstrate that basic research can develop novel therapeutic strategies to improve the prognosis of lung cancer. In this review, we summarize the crucial findings of molecular pathogenesis in lung cancer, especially NSCLC, and show the possible future direction of related molecular biological research.

DOI： 10.2482/haigan.50.329

CiNii Article

researchmap

Missense polymorphisms of PTPRJ and PTPN13 genes affect susceptibility to a variety of human cancers. International journal

Yuichiro Mita, Yukiko Yasuda, Akiko Sakai, Hiromasa Yamamoto, Shinichi Toyooka, Mehmet Gunduz, Shunsuke Tanabe, Yoshio Naomoto, Mamoru Ouchida, Kenji Shimizu

Journal of cancer research and clinical oncology 136 ( 2 ) 249 - 259 2010

Language：English

PURPOSE: We investigated the association between incidence of various cancers and four single nucleotide polymorphisms (SNPs), two each in two protein tyrosine phosphatase (PTP) genes, PTPRJ and PTPN13, by a case-control study conducted in Japan. METHODS: The study samples comprised 819 cancer-free controls and 569 cancer cases including lung, head and neck, colorectal, and esophageal cancers. RESULTS: Compared with the major homozygotes at the Arg326Gln SNP in PTPRJ, a likely homologue of the mouse SCC1 (susceptible to colon cancer), Arg/Gln or Gln/Gln genotypes exhibited an increased colorectal cancer risk with adjusted odds ratios (aOR) of 1.71 (P = 0.021) and 3.74 (P = 4.14 x 10(-4)), respectively. Increased risks were observed with one or more of the combination genotypes of Gln276Pro and Arg326Gln in PTPRJ for most cancer types (aOR range 10.13-55.08, Bonferroni-corrected P = 0.0454-7.20 x 10(-9)). In the PTPN13, major homozygotes of Ile1522Met showed an increased risk for lung squamous cell carcinomas (aOR 1.86), compared to the heterozygotes. Increased risks were observed with at least one of the combination genotypes of the two SNPs, Ile1522Met and Tyr2081Asp, for all but esophageal cancer examined (aOR 3.36-13.75), compared with double heterozygotes. Moreover, these high risks were seen also when all cancer cases were combined (aOR 1.81-6.84). CONCLUSIONS: PTPRJ and PTPN13 SNPs were found to influence susceptibility to a wide spectrum of cancers. Because allelic frequencies of these SNPs are relatively common in many ethnic groups, these findings are worthy of further study.

DOI： 10.1007/s00432-009-0656-7

PubMed

researchmap

肺移植の遠隔治療成績 : 慢性拒絶反応とその対策

大藤剛宏, 山根正修, 石原恵, 豊岡伸一, 佐野由文, 三好新一郎

移植 44 ( 6 ) 523 - 527 2009.12

閉塞性肺炎で発見された気管支過誤腫の1例

村岡孝幸, 豊岡伸一, 佐野由文, 杉本龍士郎, 原田昌明, 西山慶子, 増田紘子, 山根正修, 大藤剛宏, 三好新一郎

肺癌 49 ( 5 ) 785 - 785 2009.10

Adjuvant Chemotherapy for Completely Resected Non-Small-Cell Lung Cancer

Hiroshi Suehisa, Shinichi Toyooka

ACTA MEDICA OKAYAMA 63 ( 5 ) 223 - 230 2009.10

Language：English Publishing type：Book review, literature introduction, etc. Publisher：OKAYAMA UNIV MED SCHOOL

For many years, surgery alone was the standard treatment for patients with stage I-IIIA non-small-cell lung cancer (NSCLC). However, recent studies have demonstrated that adjuvant chemotherapy provides a survival benefit. The first adjuvant chemotherapy for NSCLC was performed in the 1960s using a key drug known as cyclophosphamide. In the 1980s and early 1990s, a new anti-cancer drug, cisplatin, was developed. The first meta-analysis of this drug was conducted by the Non-small Cell Lung Cancer Collaborative Group in 1995. This analysis comparing surgery with surgery plus chemotherapy containing cisplatin produced a hazard ratio of 0.87 and suggested an absolute benefit of chemotherapy of 5% at 5 years; this difference was not statistically significant (p = 0.08). Several clinical trials of adjuvant chemotherapy were planned after the meta-analysis conducted in 1995, but the efficacy of adjuvant chemotherapy remained a matter of controversy. However, useful evidence was reported after 2003. The International Adjuvant Lung Cancer Collaborative Group Trial (IALT) demonstrated a 4.1% improvement in survival for patients with stage I to III NSCLC. The JBR. 10 trial demonstrated a 15% improvement in 5-year survival for the adjuvant chemotherapy arm in stage IB or II (excluding T3N0) patients. The Adjuvant Navelbine International Trialist Association (ANITA) trial reported that the overall survival at 5 years improved by 8.6% in the chemotherapy arm and that this survival rate was maintained at 7 years (8.4%) in stage II and IIIA patients. A meta-analysis based on collected and pooled individual patient data from the 5 largest randomized trials was conducted by the Lung Adjuvant Cisplatin Evaluation (LACE). This analysis demonstrated that cisplatin-based adjuvant chemotherapy improved survival in patients with stage II or III cancer. Alternatively, uracil-tegafur has been developed and tested in Japan. The Japan Lung Cancer Research Group (JLCRG) on Postsurgical Adjuvant Chemotherapy reported a 5-year overall survival advantage of 11% in the uracil-tegafur group patients with stage IB cancer. The efficacy of adjuvant chemotherapy with uracil-tegafur was confirmed in a meta-analysis. In conclusion, the results of phase III trials and a meta-analysis have confirmed the benefit of adjuvant chemotherapy for resected stage 113, II, and IIIA NSCLC.

Web of Science

researchmap

非小細胞肺癌術後補助療法としてカルボプラチン+パクリタキセルとUFTとの多施設共同無作為化比較臨床試験

中村廣繁, 豊岡伸一, 堀田勝幸, 中田昌男, 奥村典仁, 多田弘人, 山下素弘, 渡辺直樹, 梶原伸介, 岡部和倫, 松尾恵太郎, 青江基, 伊達洋至, 三好新一郎, 坂本純一, 瀬戸内肺癌研究会

肺癌 49 ( 5 ) 616 - 616 2009.10

A case of hiatus hernia which progressed after lung surgery and required hernia repair due to severe cardio-pulmonary failure

OKADA Masanori, TAO Hiroyuki, YAMANE Masaomi, OTO Takahiro, SANO Yoshifumi, TOYOOKA Shinichi

The Journal of the Japanese Association for Chest Surgery 23 ( 6 ) 881 - 885 2009.9

Language：Japanese Publisher：特定非営利活動法人日本呼吸器外科学会

A 74-year-old woman with chronic hiatus hernia of the mixed type was diagnosed with lung cancer and referred for surgery. After a lobectomy with lymphadenectomy, she presented tachycardia and medication-resistant, asthma-like dyspnea. Computed tomography of the chest revealed that the hiatus hernia had become aggravated and the protruding stomach was compressing the heart and left lung. Hernia repair was performed as an emergency surgery. Her cardio-pulmonary dysfunction recovered immediately after the operation. It is important to note that patients with hiatus hernia may possibly develop life-threatening cardio-pulmonary dysfunction after thoracic surgery. In such cases, hernia repair should be considered.

CiNii Article

researchmap

A case of solitary bronchial papilloma mimicking hilar lung cancer on positron emission tomography

TAO Hiroyuki, KOMOTO Junichi, OTO Takahiro, YAMANE Masaomi, TOYOOKA Shinichi, SANO Yoshifumi

The Journal of the Japanese Association for Chest Surgery 23 ( 6 ) 816 - 820 2009.9

Language：Japanese Publisher：特定非営利活動法人日本呼吸器外科学会

We report the case of a solitary bronchial papilloma with middle lobe syndrome that was speculated to be a hilar malignant tumor on <SUP>18</SUP>F-deoxyglucose positron emission tomography (FDG-PET). A 66-year-old woman was referred to our hospital complaining of a continuous productive cough. Computed-tomography of the chest showed a right hilar mass and consecutive bronchial tumor with heterogeneous enhancement. The bronchial tumor and hilar mass were FDG-PET-positive, with a maximum standard uptake value of 10.6, suggesting a malignant neoplasm. Bronchofiberscopic tumor biopsy was repeated twice, but only suggested atypical squamous epithelium. An open biopsy of the bronchial tumor through a right thoracotomy was conducted, and intra-operative frozen sectioning of the bronchial tumor led to a diagnosis of papilloma. Then, a right middle sleeve-lobectomy was performed. The right hilar mass turned out to be mucopurulent secretions filling, obstructing, and dilating the right middle bronchus. The pathological diagnosis was mixed squamous cell and glandular papilloma. The patient is doing well without any signs of recurrence one year after the operation. It is important to note that bronchial tumors with obstructive pneumonia can present hilar cancer-like findings on FDG-PET.

CiNii Article

researchmap

The antitumor effect of orally active heat shock protein 90 Inhibitor, 17-DMAG, on the growth of gefitinib-resistant non-small cell lung cancer

Takafumi Kubo, Shinichi Toyooka, Masaru Jida, Tatsuro Hayashi, Hiroki Otani, Hiromasa Yamamoto, Naruyuki Kobayashi, Junichi Soh, Yoshifumi Sano

JOURNAL OF THORACIC ONCOLOGY 4 ( 9 ) S550 - S550 2009.9

Mutations and copy number gains of KRAS gene correlate with biological activity of ras and clinical outcome in lung adenocarcinomas

Junichi Soh, William Lockwo-od, Hiromasa Yamamoto, Hisayuki Shigemetsu, Raj Chai, Tang Ximing, Marileila Garcia, Tonu Vooder, Retlav Roosipuu, Ignacio Wistuba, Calum MacAulay, Shinichi Toyooka, John Minna, Wan Lam, Adi Gazdar

JOURNAL OF THORACIC ONCOLOGY 4 ( 9 ) S282 - S282 2009.9

Whole genomic analysis of a case of lung cancer with high-level MET gene amplification

Hiromasa Yamamoto, William W. Lockwood, Takafumi Kubo, Junichi Soh, Yoshifumi Sano, Adi F. Gazdar, Wan L. Lam, Shinichi Toyooka

JOURNAL OF THORACIC ONCOLOGY 4 ( 9 ) S642 - S642 2009.9

Percutaneous computed tomography-guided lung biopsy and pleural dissemination: an assessment by intraoperative pleural lavage cytology

Yoshifumi Sano, Shinichi Toyooka, Takahiro Oto, Masaomi Yamane, Takao Hiraki, Hideo Gobara, Susumu Kanazawa

JOURNAL OF THORACIC ONCOLOGY 4 ( 9 ) S586 - S586 2009.9

Costimulatory blockadeによる肺移植後免疫寛容とその阻害因子

岡崎幹生, 杉本誠一郎, 山根正修, 豊岡伸一, 大藤剛宏, 佐野由文, 三好新一郎, KREISEL Daniel

移植 44 313 2009.9

Antiproliferative effects of a novel mTOR inhibitor (Temsirolimus) provide the prolonged survival in a pleural dissemination model using non-small cell lung cancer cells

Toshiaki Ohara, Yoshio Naomoto, Yasuko Tomono, Shinichi Toyooka, Toshio Nishikawa, Kazufumi Sakurama, Seishi Nishitani, Huifang Hao, Xiaohong Bao, Shunsuke Tanabe, Yasuhiro Fujiwara, Takayuki Motoki, Munenori Takaoka, Yasuhiro Shirakawa, Tomoki Yamatsuji, Junji Matsuoka, Noriaki Tanaka

CANCER RESEARCH 69 2009.5

Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) occur together frequently in human lung and other cancers

Junichi Soh, Naoki Okumura, William Lockwood, Hiromasa Yamamoto, Hisayuki Shigematsu, Wei Zhang, Ignacio Wistuba, Calum MacAulay, Marileila Garcia, Stephan Lam, Shinichi Toyooka, John Minna, Wan Lam, Adi Gazdar

CANCER RESEARCH 69 2009.5

PE-511 Predictor of Post-operative Left Ventricular Dysfunction after Lung Transplantation in Patients with Pulmonary Hypertention by Radionuclide Ventriculography(PE086,Pulmonary Circulation (H),Poster Session (English),The 73rd Annual Scientific Meeting of the Japanese Circulation Society)

Kawada Satoshi, Fuke Soichiro, Kusano Kengo, Toyooka Shinichi, Sano Yoshihumi, Date Hiroshi, Sano Shunji, Okazaki Megumi

Circulation journal : official journal of the Japanese Circulation Society 73 528 - 529 2009.3

WS-3-8 大腸癌および腎癌肺転移に対するラジオ波焼灼術の有用性(転移性肺腫瘍に対するエビデンスに基づいた外科治療,ワークショップ,第109回日本外科学会定期学術集会)

佐野由文, 豊岡伸一, 岡崎幹生, 山根正修, 大藤剛宏, 金澤右

日本外科学会雑誌 110 ( 2 ) 2009.2

HP-161-1 骨髄細胞局所投与によるラット異所性移植気管における血管新生(肺・気管・気管支(移植・虚血再還流),ハイブリッドポスター,第109回日本外科学会定期学術集会)

田尾裕之, 岡崎幹生, 山根正修, 豊岡伸一, 大藤剛宏, 佐野由文

日本外科学会雑誌 110 ( 2 ) 2009.2

　 PREV - NEXT 　

< TOYOOKA Shinichi >

MISC - TOYOOKA Shinichi